Epidemiology, Patients' Journey and Healthcare Costs in Early-Stage Non-Small-Cell Lung Carcinoma: A Real-World Evidence Analysis in Italy.

As reported in Supplementary Table S4 , during the second and third years, patients receiving lung cancer-related medications witnessed a decreasing trend, while no variations were observed in relation to the consumption of other drugs, as well as in costs related to tests/visits (including PET/CT and CT scan).

also in 47,180 other papers

In fact, we observed an almost 80% decrease in lung cancer-related hospitalization costs throughout the years (EUR 10,243 during the first year and EUR 671 and 694 during the second and third years) ( Supplementary Table S5 ); conversely, costs related to lung cancer medications witnessed an increasing trend (almost 22%) in the second/third years.

also in 63,971 other papers